Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Polycystic Ovary Syndrome 4Prostatic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Rectal Neoplasms 1Psoriasis 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pain 1Ovarian Neoplasms 1Osteoarthritis 1Obesity 1Neoplasms 1Neoplasm, Residual 1Multiple Sclerosis 1Lipid Metabolism Disorders 1Inflammation 1Healthy Subject 1Dyspareunia 1Diabetes Mellitus 1Crohn Disease 1Cardiovascular Diseases 1Breast Neoplasms, Male 1Breast Feeding 1Breast Carcinoma In Situ 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Aggressive Periodontitis 1

Interventions

Interferon beta-1b 2Fingolimod Hydrochloride 2teriflunomide 1nabiximols 1Platelet Transfusion 1OM 89 1Natalizumab 1Mn-PyC3A 1Magnetic Resonance Imaging 1Interferon beta-1a 1Fish Oils 1Dimethyl Fumarate 1Blood Specimen Collection 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Sclerosis × Fish Oils × Clear all
NCT02939079 2019-05-14

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

Isfahan University of Medical Sciences

Phase 2/3 Completed
50 enrolled 20 charts

Multiple Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡